A dynamic paracrine FGF21-mTORC1/mTORC2 signaling axis regulates thymus function across the lifespan 3308

Abstract Description Thymic stromal cells (TSCs), particularly cortical thymic epithelial cells (cTECs), are the primary targets of age-associated thymic atrophy, but the mechanisms regulating thymic growth and atrophy remain relatively obscure. Recent studies characterizing the TSC transcriptional response to age-associated thymus atrophy and experimental regeneration suggested that growth factors expressed in medullary TECs (mTECs) drive paracrine mTOR signaling in cTECs to maintain their unique morphology, regulating thymus size. To test these hypotheses, we generated a bi-cistronic knock-in (KI) mouse model in which the mTOR-activating ligand FGF21 is expressed under the control of the Lactoperoxidase gene (LPOFGF21), directing expression broadly but specifically in mTECs in the thymus. mTEC-derived FGF21 overexpression promotes temporally distinct mTORC1 and mTORC2 signaling in cTECs, promotes thymus and individual cTEC growth and maintenance, increases T cell responsiveness to influenza, and diminishes indicators of peripheral autoimmunity in older mice. The effects of FGF21 overexpression on thymus size and mTOR signaling were abrogated by rapamycin treatment, consistent with a role for mTOR-mediated FGF21 signaling in cTEC growth and maintenance. These results reveal a novel molecular mechanism by which paracrine signaling regulates thymus size and function throughout the lifespan, as well as novel potential therapeutic targets for improving T cell function in the aging population. Funding Sources Supported by NIH R01AG086271 (A.V.G), R21AI154109 (A.V.G), and R21AG081709 (A.V.G); the DiGeorge Syndrome Research Fund (G.A.H.), Swiss National Science Foundation grant IZLJZ3_171050; 310030_184672 (G.A.H.), Medical Research Council grant MR/S036407/1 (G.A.H.), Wellcome Trust grant 105045/Z/14/Z, and 211944/Z/18/Z (G.A.H) Topic Categories Hematopoiesis and Immune System Development (HEM)

Authors

Institutions

Publication Details

Journal
The Journal of Immunology
Published
2025-11-01
DOI
https://doi.org/10.1093/jimmun/vkaf283.1124
Primary Topic
Myasthenia Gravis and Thymoma
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A dynamic paracrine FGF21-mTORC1/mTORC2 signaling axis regulates thymus function across the lifespan 3308

Sarah A. Wedemeyer
The Journal of Immunology
Myasthenia Gravis and Thymoma
article

A dynamic paracrine FGF21-mTORC1/mTORC2 signaling axis regulates thymus function across the lifespan 3308

Sarah A. Wedemeyer
article en

Abstract

Abstract Description Thymic stromal cells (TSCs), particularly cortical thymic epithelial cells (cTECs), are the primary targets of age-associated thymic atrophy, but the mechanisms regulating thymic growth and atrophy remain relatively obscure. Recent studies characterizing the TSC transcriptional response to age-associated thymus atrophy and experimental regeneration suggested that growth factors expressed in medullary TECs (mTECs) drive paracrine mTOR signaling in cTECs to maintain their unique morphology, regulating thymus size. To test these hypotheses, we generated a bi-cistronic knock-in (KI) mouse model in which the mTOR-activating ligand FGF21 is expressed under the control of the Lactoperoxidase gene (LPOFGF21), directing expression broadly but specifically in mTECs in the thymus. mTEC-derived FGF21 overexpression promotes temporally distinct mTORC1 and mTORC2 signaling in cTECs, promotes thymus and individual cTEC growth and maintenance, increases T cell responsiveness to influenza, and diminishes indicators of peripheral autoimmunity in older mice. The effects of FGF21 overexpression on thymus size and mTOR signaling were abrogated by rapamycin treatment, consistent with a role for mTOR-mediated FGF21 signaling in cTEC growth and maintenance. These results reveal a novel molecular mechanism by which paracrine signaling regulates thymus size and function throughout the lifespan, as well as novel potential therapeutic targets for improving T cell function in the aging population. Funding Sources Supported by NIH R01AG086271 (A.V.G), R21AI154109 (A.V.G), and R21AG081709 (A.V.G); the DiGeorge Syndrome Research Fund (G.A.H.), Swiss National Science Foundation grant IZLJZ3_171050; 310030_184672 (G.A.H.), Medical Research Council grant MR/S036407/1 (G.A.H.), Wellcome Trust grant 105045/Z/14/Z, and 211944/Z/18/Z (G.A.H) Topic Categories Hematopoiesis and Immune System Development (HEM)

The Journal of ImmunologyVol. 214(Supplement_1)
The University of Texas at San Antonio Health Science Center (US)
National Science Foundation, Wellcome Trust, Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, National Institutes of Health, Medical Research Council, National Cancer Institute
Openalex Percentile: Top 51%
Myasthenia Gravis and Thymoma
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.